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Health disparities are a major contributor in chronic obstructive pulmonary disease
(COPD) around the world.1,2 COPD is not unique, as health disparities are found with
other chronic diseases and throughout the continuum of care. However, the influence
of health disparities and socioeconomic status (SES) on the etiology and outcomes of
major noncommunicable chronic diseases is more evident with COPD. Environmental
risk factors for developing COPD are more common in low SES people, which include
tobacco smoking, environmental tobacco smoke (ETS), indoor and outdoor air pollution, and biomass fuel (BF) exposure.1 Furthermore, genetic tendencies for asthma3
and nicotine addiction4 may contribute to disparities in COPD since some race/ethnic/
tribal groups are overrepresented in low SES stratum in different countries. According
to the World Health Organization (WHO), .90% of COPD deaths occur in lowincome and middle-income countries (LMICs).5 In an effort to reduce the magnitude
of COPD in populations that bear a disproportionate burden of disease, initiatives by
national and international organizations are presently targeting disparities in respiratory diseases. Continuity in disease prevention and delivery of health care as well as
access to appropriate medications for COPD needs to be provided to all segments of
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Abstract: The global burden of chronic obstructive pulmonary disease (COPD) continues to
grow in part due to better outcomes in other major diseases and in part because a substantial
portion of the worldwide population continues to be exposed to inhalant toxins. However,
a disproportionate burden of COPD occurs in people of low socioeconomic status (SES) due to
differences in health behaviors, sociopolitical factors, and social and structural environmental
exposures. Tobacco use, occupations with exposure to inhalant toxins, and indoor biomass fuel
(BF) exposure are more common in low SES populations. Not only does SES affect the risk of
developing COPD and etiologies, it is also associated with worsened COPD health outcomes.
Effective interventions in these people are needed to decrease these disparities. Efforts that may
help lessen these health inequities in low SES include 1) better surveillance targeting diagnosed
and undiagnosed COPD in disadvantaged people, 2) educating the public and those involved
in health care provision about the disease, 3) improving access to cost-effective and affordable health care, and 4) markedly increasing the efforts to prevent disease through smoking
cessation, minimizing use and exposure to BF, and decreasing occupational exposures. COPD
is considered to be one the most preventable major causes of death from a chronic disease in
the world; therefore, effective interventions could have a major impact on reducing the global
burden of the disease, especially in socioeconomically disadvantaged populations.
Keywords: health disparities, COPD, interventions, prevention, management, international,
socioeconomic status
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the population, particularly the disadvantaged. This article
provides perspective on the health disparities related to SES
in COPD and strategies that may help in efforts to provide
quality health care in this population.

Methods
We conducted systematic searches of the literature in English
or articles with English abstracts using bibliographic databases of PubMed/Medline (National Library of Medicine
and National Institutes of Health), Embase, and the Cochrane
database. We used the keywords “COPD” or “emphysema”
or “chronic bronchitis”, “socioeconomic status”, “poverty”,
“health disparities”, “prevalence”, and “outcomes”.

Definitions of health disparities
and SES
For all chronic diseases, multiple socioeconomic factors
contribute to health disparities including income, education,
residential segregation, genetic susceptibility, stress, access
to health care, social and physical environment, and employment. Unequal access to quality health care is the foundation
of health disparities. However, in general, health disparities
are not only a function of whether an individual can afford to
buy goods and services that aid good health but also include
health behaviors related to lifestyle and the environment.
Unhealthy behaviors such as tobacco smoking often provide
pleasure and relaxation that help regulate mood,6 particularly
in low SES people who have significant stressors in life.
Disparities exist when differences in health outcomes
or health determinants are observed between populations.
A number of organizations have defined health-related disparities including the WHO,7 the United States (US) Office of
Disease Prevention and Health Promotion,6 and international
pulmonary organizations such as the American Thoracic
Society (ATS), and European Respiratory Society (ERS).8
The WHO defines health disparities as:
Inequalities that exist when members of certain population
groups do not benefit from the same health status as other
groups. Further, these disparities occur in the provision of
healthcare and access to healthcare across different racial,
ethnic and socioeconomic groups.7

In Healthy People 2020, the US Office of Disease Prevention and Health Promotion describes disadvantaged populations as:
Groups of people who have experienced greater obstacles
to health based on their racial or ethnic group; religion,
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SES, gender, age, occupation, mental health, cognitive,
sensory or physical disability or other characteristics linked
to discrimination or exclusion.6

A joint 2013 ATS/ERS committee published a policy
statement broadly defining disparities in respiratory health
similar to the Healthy People 2020 definition – specifically
“significant differences in respiratory health that are closely
linked to racial ancestry, social, economic and/or environmental differences”.8
SES is a composite assessment of a person’s economic
and social position in a society based on several factors
including income, occupation, home and neighborhood
environment, and educational attainment. These factors
are correlated, and it is difficult to identify the independent
contribution of each factor on the composite assessment of
SES. However, many investigators use a single component of
SES, for example, educational attainment or annual income,
to represent a person’s overall economic and social position
in their country. In studies evaluating the SES, education
is often defined by years of educational attainment (ie, less
than high school (secondary school), high school (secondary
school graduate), some college/university, or college/
university graduate.
Income is usually defined by individual annual income
or cumulative household income. Since the median annual
income varies widely between countries, the income-based
definition of “low SES” can also vary widely across the
globe. The WHO defines extreme poverty as an individual
income less than or equal to the equivalent of 2.00 US dollar
(USD) per day.9 The United Kingdom, like most of the
developed world, defines poverty as 60% of median income
in a country. However, in the US, poverty is defined by the
US Census Bureau by comparing income to be three times
the cost of a minimum food diet in 1963, which is updated
annually for inflation and adjusted for family size, composition (ie, number of adults and children in a household),
and age of householders.10 For example, in 2014, the US
poverty level for a family of five persons was ~29,000 USD
annual income, which was 53.7% of the 54,000 USD median
household income.
Other infrequently used measures of SES include
geographical area deprivation which categorizes neighborhoods by global positioning system and median income;
number of persons living in household; and occupation (eg,
manual labor in industry, service industry, office worker,
agricultural worker, housewife, professional worker, and
machine operator).11
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Health disparities in respiratory
diseases
Health disparities are more commonly seen for respiratory
diseases. The lowest socioeconomic groups are up to 14 times
more likely to have respiratory disease than the highest
group.8 An individual’s socioeconomic position usually has
continuous and numerous health effects that accumulate over
a lifetime, and these long-term environmental exposures
lead to diseases such as COPD. Disparities related to SES
are evident for a number of respiratory diseases including
asthma, COPD, lung cancer, and respiratory tract infections
such as tuberculosis.8 Lung cancer is clearly more likely to
occur in people of low SES, even when adjusting for tobacco
use.10 In some countries, treated tuberculosis is a relatively
common cause of COPD in people of low SES living in
low-income, multiple person dwellings.1
Compared to other common causes of morbidity and
death, COPD appears to be more socioeconomically related
than others. In a study considering various causes of death, the
association was stronger for COPD than cardiac disease.11
This is principally true because smoking and environment
play leading roles in lung disease development – and people
of lower SES tend to have substantially greater exposures
to both of these factors. Although asthma affects all ethnic
groups, suboptimal outcomes are disproportionately shared
by certain minority groups and economically disadvantaged
persons.12,13 However, low income has a greater influence on
COPD prevalence than on asthma prevalence,14 this may be
because asthma is more genetically driven whereas COPD
is more environmentally induced.
According to the WHO, the social determinants of
health are mostly responsible for the health inequities seen
within and between countries.15 The WHO defines social
determinants of health as the conditions in which people
are born, grow, work, live, age, and the wider set of forces

Defining and targeting health disparities in COPD

and systems shaping the conditions of daily life. Whitehead
described the principal determinants of health disparities
arising from multiple sources; Table 1 provides the correlations relative to COPD.16

Health disparities in COPD
As shown in Tables 2–4, there is a strong relationship
between COPD and SES. 17–58 Environmental factors
contributing to the development or worsening of COPD
include use of tobacco products, occupation, prenatal
and childhood exposures, respiratory tract infections, air
pollution, and housing conditions including the use of
BF, all of which are more likely to be present in low SES
people. In developed countries, the major risk factor for
COPD is long-term tobacco product use, whereas in less
developed countries, the conditions of the home (BF) and
work setting (dust, fumes, and vapors) often have a more
substantial impact on health than either personal position
in society or tobacco exposure. Consistent with this, a
multinational study from the 1970s and 1980s showed
there was a poor correlation between COPD mortality
and cigarette smoking data among 31 countries.59 More
recently, the Burden of Obstructive Lung Disease (BOLD)
study showed a better correlation of COPD prevalence and
tobacco use; however, the relationship was not strong in
all settings.60

SES and respiratory symptoms
One would expect that if SES is a risk factor for developing COPD, it would also increase the risk of respiratory
symptoms. Studies over the last 2 decades have shown
that people of low SES exhibit lower lung function and
more respiratory symptoms than those in higher SES
groups – typically at least a several-fold difference
(Table 2). Whether using forced expiratory volume in

Table 1 Whitehead’s principal determinants of health disparities and COPD correlates
General determinants of health disparities

Corresponding determinants for COPD

Natural biologic variation
Health-damaging behavior of individuals
Transient health advantage for people who adopt new
behaviors first
Health-damaging behavior in which the degree of choice
of lifestyles is severely restricted
Exposure to unhealthy living and working conditions
Inadequate access to health care
Natural selection leading to the tendency for the sick
to move down the social hierarchy

Genetic susceptibilities
Smoking tobacco and/or biomass fuel use
Educated people making behavioral changes more readily than those with
lower levels of education
People being born into and remaining in impoverished and low education
settings
Exposure to environmental (second-hand) smoke and indoor biomass fuels
People in lower socioeconomic status and having less health care access
People with advanced COPD become disabled due to disease

Note: Data adapted from Whitehead M. The concepts and principles of equity and health. Health Promotion Int. 1991;6:217–228.16
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Table 2 Relationship between socioeconomic status and respiratory measures
References

Population (description
and N)

Socioeconomic status
measure(s)

Outcome measure(s)

Main findings

Trinder
et al17

General practices in UK
(N=4,237)

Occupation of
householder

Respiratory symptoms

Shohami
et al18

Adults in UK attending general
medical practices (N=22,675)

Occupation, education
level, and area deprivation

Lung function impairment

Welle
et al19
Schikowski
et al20

Norwegian general population
survey (N=1,275)
Germany (N=1,251, women only)

Educational level

DLCO

Education level,
occupation, and residence

Smith
et al21

Chinese population (never
smokers) in ten regions
(N=307,000)
Cross-section of adults in ten
diverse populations across China
(N=500,000 adults)
Cross-sectional survey in one
US state (N=4,300 adults)

Household income and
education level

Lung function,
respiratory symptoms,
and air particulate matter
Prevalence of AO

Severity of respiratory symptoms worse
in people with manual occupation in the
presence of tobacco use
Occupation, educational level, and living
in area of deprivation associated with
worse lung function
DLCO related to education in men, not
women
Low education more likely to suffer
from low FEV1 and were occupationally
exposed to particulate matter .10 ppm
AO associated with lower education
and income

Kurmi
et al22
Liu et al23

Prevalence of AO and
respiratory symptoms

AO inversely related to annual income

Education level

Prevalence of respiratory
symptoms

Low educational level associated
with higher frequency of respiratory
symptoms, including frequent
productive cough, dyspnea, and SOB
affects ADLs

Abbreviations: ADLs, activities of daily life; AO, airflow obstruction; DLCO, diffusion capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 second;
ppm, parts per million; SOB, shortness of breath.

1 second (FEV1), the presence of airflow obstruction (AO),
or respiratory symptoms, all the studies show more impairment in people with low SES and whether it is based on
income, education, or occupation.

that two-thirds of subjects with COPD were in the lowest
SES group based on education.

SES and COPD prevalence

Risk factors for COPD in the lower
SES population
Tobacco use

Table 3 shows studies of the relationship between SES and
COPD prevalence, often showing .1.5 to three-fold greater
in disadvantaged people; this holds true whether income or
educational levels are used to define SES. The prevalence
of emphysema, because it is more common in smokers than
those exposed to BF, may exhibit a different relationship to
SES depending on the country.61 The BOLD and PLATINO
studies have been the most extensive studies of COPD
internationally – both support the relationship between
poverty and higher COPD prevalence.60,62
In most countries, people of low SES account for the
majority of all COPD patients. In the US, although low
SES people constitute the minority of the overall population
(,20%), they account for nearly two-thirds of all patients
with COPD63,64 or AO.22 Similarly, in a study of the Chinese
population, people with low educational level accounted for
43% of the survey population in rural areas but 81% of those
were with COPD.65 Finish33 and Korean40 studies reported

Long-term tobacco use is the most common cause of COPD
in developed countries – this is most evident in people with
low SES due to relatively high rates of tobacco use. In the
US, where overall current use of tobacco is ,20% of adults,
rates of current smoking are three- to fivefold higher in those
with less than a high school education compared with college graduates.66 One of the authors of this article undertook
a quality improvement project in four indigent medical
clinics and found that current smoking rates were .70%
among adult patients (R Pleasants, Duke Asthma, Allergy,
and Airways Center, Duke University School of Medicine,
personal communication, June, 2013). Often, these exposures
begin early in life, as children in low SES settings are more
likely to be exposed to environmental tobacco smoke from
household members and these same people are more likely
to eventually smoke tobacco products.
Some epidemiologic studies (for example, Twyman
et al67) have shown that low education is associated with

2478
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Table 3 Relationship between socioeconomic status and COPD prevalence
References

Population, description,
and N

Socioeconomic
status measure(s)

Outcome measure(s)

Main findings

Bakke et al24

Cross-sectional study of general
adult population in Norway
(N=1,512)
Adults from 40 general practices
in the UK (N=28,080)

Occupation

Asthma and COPD
prevalence

Deprivation score
based on residence

Disease prevalence
including COPD

Chen et al26

National population survey in
Canada (N=7,210)

Income

COPD disease
prevalence

OR of 3.6 for obstructive lung disease
in people with high degree of airborne
exposure
Emphysema and chronic bronchitis
relative index of 2.72 and 2.27,
respectively (values higher than most
other conditions)
For low income persons OR =3.7 for
males and 2.4 for females

Marmot et al27

Civil servants in London, UK
(N=10,308)
Adults in Sweden (N=12,071)

Occupation
(employment grade)
Occupation, social
position, and
residence location
Occupation

Chronic bronchitis
prevalence
Prevalence of CBE and
respiratory symptoms
COPD incidence over
10 years in subjects with
respiratory symptoms

OR for CB for men 1.44 and women
1.21
CBE more common in unskilled
and semiskilled workers, low social
position
Manual workers had an OR =1.78 vs
professionals. Low education level had
an OR =1.73

Eachus et al25

Montnemery
et al28
Lindberg et al29

Sweden (N=1,165)

Ellison-Loschmann
et al30

European Community
respiratory health Survey in
Europe, Australia, New Zealand,
and the US
Norwegian prescription
database of COPD patients
(N=62,882)
Finland – national populationwide survey (N=6,525)

Educational level and
occupational class

Prevalence and
incidence of chronic
bronchitis

Low educational and occupational
levels (prevalence ratio =1.9 and 1.8,
respectively)

Educational level and
level of unemployment
in community
Education and
household income

COPD prevalence

Multi-ethnic study of arthero
sclerosis at multiple sites in
the US (N=3,706)
People’s Republic of China
(31 provinces), (N=49,363)

Education, household
income, and wealth
indicators
Education and
household income

Degree of emphysema
on computed
tomography scan
COPD prevalence by
self-report

Herrick et al36

Cross-sectional population
study in one US state
(N=25,986)

Annual household
income and highest
level of education

COPD prevalence

Burney et al60

Multicenter (n=22 countries),
international study burden
of obstructive lung disease
(N=15,355)

Poverty as measured
by GNI of countries

COPD prevalence

Communities with low educational
levels and unemployment associated
with higher risk of COPD
Education significant risk factor for
COPD, whereas low household income
was a risk factor for asthma
Higher percent of emphysema in people
with lower high school education,
annual income, and wealth
SES predictive of COPD risk
independent of smoking and rural vs
urban residence
COPD prevalence threefold greater
between highest and lowest income
levels as well as between lowest and
highest education levels
COPD prevalence fivefold greater
between highest and lowest income
levels as well as between lowest and
highest education levels

Kainu et al37

Finnish population (N=8,000,
COPD N=628)

Occupation

COPD prevalence

Prevalence higher in manual than
nonmanual occupations

Golec et al38

Polish farmers (N=64)
Swedish never-smokers with
obstructive lung disease
(N=967)

Size of farm

COPD prevalence

Lower SES in COPD patients

Education level,
occupation

Korean never smokers with
COPD (N=3,473)
Canadian cross-sectional study
in general adult population
(N=5,176)

Educational level,
occupation
Educational level

Proportion of
nonsmokers with
COPD who had
occupational exposures
COPD prevalence

OR of COPD related to
occupation =0.72 in college graduates
vs those with less than high-school
education
Low education level and manual labor
were risk factors for COPD
Low education level associated with
higher prevalence in both never and
ever-smokers

Halvorsen and
Matrinussen32
Karnevisto et al33

Lovasi et al34

Yin et al35

Hagstad et al39

Lee et al40
Tan et al41

COPD and asthma
prevalence

COPD prevalence in
ever and never-smokers

Abbreviations: CB, chronic bronchitis; CBE, chronic bronchitis/emphysema; COPD, chronic obstructive pulmonary disease; GNI, gross national income; OR, odds ratio;
SES, socioeconomic status.
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Table 4 Effect of socioeconomic status on respiratory-related outcomes in chronic obstructive pulmonary disease
References

Population

SES measure

Outcome measure(s)

Main findings

Prescott et al

Copenhagen, Denmark
general population
(N=14,223)

Educational level and
household income

Hospitalization for COPD

Van Rossum et al42

the Netherlands
(N=18,001)

Occupation

Mortality

Steenland et al11

Adults in 27 states in the
US, American Cancer
Society population
(N=1,330,886)
European data from
numerous countries
(N=1,000,000 deaths)

Occupation

All cause and cause-specific
mortality

Higher rates of hospitalization
related to income and education
levels (independent of smoking
history)
COPD had highest rate of
increased mortality related to
occupation compared with other
common causes of death
SES gradient most substantial for
all specific causes of death

Education level

Antonelli-Incazi
et al45

Elderly in Rome, Italy

Blanc et al46

US population survey of
COPD patients (N=427)
National survey of 30
provinces in the People’s
Republic of China
(N=169,871)

Income based upon
census tract estimate for
residence
Educational level and
annual income
Education, residence
(urban vs rural)

Mortality rate in loweducational groups expressed
as a proportion of mortality
rate in high-educational groups
Hospitalization rate of COPD
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43

Huisman et al44

Reilly et al47

Schane et al48

Wong et al49

Lewis et al10

Arne et al50

Tiotropium use
Mortality

National cross-sectional
US survey (N=18,858
total N=1,736 COPD
patients)
Data from St Paul’s
Hospital in Vancouver,
BC, Canada

Income and education

Risk factors for depression in
COPD vs non-COPD

Marital status and need for
social work consultation
while in hospital

Hospital LOS and readmission
rate in AECOPD patients

National Longitudinal
Mortality Study in the US
(N=184,924)
Sweden, survey of 55
municipalities (N=1,475)

Marital status, education,
health insurance, poverty
level, and occupation
Education level,
employment status, and
social support
Deprivation index

Mortality in a general adult
population
Health status and quality of
life in COPD vs non-COPD
subjects
Hospitalizations for COPD

Calderón-Larrañaga
et al51

UK, national crosssectional study
(N=53,676,021)

Miravitlles et al52

Spain, nationwide survey
(N=4,574)
CA, in the US (N=1,202)
(insured COPD patients)

Education level and
occupation
Education and income
levels

HrQOL in COPD patients

CA, in the US, population
survey in persons
.55 years (N=277)

Health literacy

COPD-related health status
and COPD-related ED
or hospitalizations using
multifactorial analysis adjusted
for income and educational levels

Eisner et al31

Omachi et al53

Physical impairment (6-minute
walk), pulmonary function,
and disease severity including
BODE index

Low education groups had highest
mortality including COPD, cancer,
and heart disease
Relative risk for females with
COPD 3.3 and males 4.3 (higher
than other diseases)
Less use of tiotropium with lower
SES (OR =0.3)
Relative risk of death 2.37
and 2.47 for men and women,
respectively. RR for urban vs
rural residence 2.14 and 1.79,
respectively
Less than HS education showed
OR =1.63 for depression

Marital status and need for social
work intervention associated with
prolonged LOS and readmission
for AECOPD
Education, marital status, and
income predictive of mortality, not
seen with insured vs uninsured
Lack of social support and low
economic status associated with
poorer health status in COPD
Deprivation and smoking
prevalence were variables with
highest explanatory power,
accounting for 59.3% and 51.4%
of the total variance, respectively
Worse HrQOL in low education
level and in unskilled workers
Low SES associated with worse
physical impairment, pulmonary,
function, and disease severity in
a COPD population with broad
access to health care
Poorer health literacy associated
with worse health status, HrQOL,
and ED and hospitalizations for
COPD

(Continued)

2480

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

International Journal of COPD 2016:11

Dovepress

Defining and targeting health disparities in COPD

Table 4 (Continued)
References

Population

SES measure

Outcome measure(s)

Main findings

McAllister et al

All Scottish residents (UK)

Hospitalization rates in COPD
associated with deprivation
index and winter season

SES and winter act synergistically
on rate of COPD hospitalizations

Gershon et al55

ON, Canada

Scottish Index of Multiple
Deprivation (measure
using multiple domains
such as income, housing,
access, education)
Average household
income based on
residence

Mortality of COPD

Lange et al56

Copenhagen, Denmark
(N=6,590) adults with
COPD

AECOPD, hospital admissions,
mortality

Trachtenberg
et al57

Administrative database
in Winnipeg, Canada
N=34,741 asthma and
COPD)
US Medicare beneficiaries
with COPD

Education ,8 years,
8–10 years, .10 years
with some college or
completed college
Census-based household
income

Although overall COPD mortality
decreased between 1966 and 2012,
differences in COPD mortality
between low and high income
widened over the study period
Highest risk of AECOPD,
low lung function, and highest
respiratory symptoms

Hospitalizations for asthma or
COPD

Lower SES associated with higher
risk of hospitalizations

Socioeconomic status
based on if Medicaid
eligible (low SES)

Burn injuries related to
oxygen use

Twofold risk of oxygen-related
burn injuries in low SES people
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Abbreviations: AECOPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; ED, emergency department; HrQOL, health-related quality of life;
LOS, length of stay; OR, odds ratio; RR, relative risk; SES, socioeconomic status.

lower odds of quitting tobacco compared with persons of
higher educational attainment. Some hypotheses include
1) impoverished people are less likely to seek treatment for
tobacco addiction because of significant life stressors, 2)
smoking is often socially accepted among their family and
peers, 3) they have lower levels of knowledge of benefits
of smoking cessation drug therapies, 4) health care providers believe that this population is less interested in quitting
smoking, 5) they have higher rates of mental health issues
including multisubstance abuse, and 6) genetics. Though
these are hypothesized explanations for the disparity in
smoking cessation rates in low SES groups, there are no
randomized controlled data to support a causal relationship.
In addition, many epidemiologic studies often leave out key
variables in their analysis. One study found that smoking
behaviors including age of initiation, intensity of tobacco
use, and smoking cessation capabilities appear to be genetically related.68 In the COPD Gene trial, it was found that
in a genetic analysis of .3,000 COPD patients, the age of
onset of tobacco use and smoking cessation behavior were
related to nicotinic receptors and hepatic metabolism of
nicotine.4 Neither study examined the relationship of genetics, smoking, and SES.
However, in less-developed countries with very wide
social gradients, the poorest are unable to afford tobacco
products, and therefore, long-term tobacco use is less likely

International Journal of COPD 2016:11

to be the leading cause of COPD. In Peru where tobacco
use is very low in the adult population (3.3%), smoking
accounts for ,10% of all COPD cases. COPD was more
likely to be due to posttuberculosis infection and indoor
BF; the latter accounting for 60% of the COPD cases.69 In
some countries such as Uganda, some of the poor grow
their own tobacco and therefore have ready access to
tobacco.

Occupation

In the US, it is estimated that ~15% of COPD cases could
be attributed to inhaled particles at work such as production
of plastics, textiles and leather, building and construction,
military service, food, crops, chemicals, petroleum, and coal
mines.70 Disadvantaged people tend to be the ones working
in these environments. However, occupation-related COPD
often does not occur in isolation, as many at-risk people have
exposures to harmful particles in the household and outdoor
environments. A greater risk of COPD has been reported with
combined occupational and smoking exposures. The odds
ratios ranged from 4.0 to 6.2 for COPD among occupationally
exposed smokers, compared with 1.4–3.2 for occupationally
exposed never-smokers.71,72 In another study, the difference
between occupationally exposed never-smokers and occupationally exposed ever-smokers was reported to be even
greater (14-fold).73
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In a National Health and Nutrition Examination Survey
study in the US, occupations associated with an increased
risk of COPD were freight, stock, material handlers, records
processing and distribution clerks, sales, transportationrelated occupations, machine operators, construction trades,
and waitresses.74 The fraction of COPD attributable to work
was estimated as 19.2% overall and 31.1% among never
smokers. The majority of workers in high-risk occupations
had low income and education levels. In a more recent Swiss
study of working adults, occupational exposures to biological
dusts, mineral dusts, and gases/fumes were associated with
two- to fivefold higher incidence of COPD of at least moderate severity; however, SES measures were not reported.75

Household and outdoor pollution
Almost 3 billion of the world’s poorest rely upon solid
fuels (wood, animal dung, charcoal, crop wastes, and coal)
burned in inefficient, polluting stoves for cooking, lighting,
and heating – leading to premature deaths from respiratory and cardiovascular diseases and cancer.76 It has been
suggested that BF is a more common cause of COPD than
cigarette smoke globally.77 The use of gas stove and solid
fuels for cooking, lighting, and heating78,79 and air pollution have been linked to increased respiratory symptoms,
impaired lung function,80–82 and development of COPD.83,84
Although the role of air pollution in causing COPD is not
clear, high levels of outdoor pollution are an important
contributor to an increased risk of acute exacerbations of
COPD85 and possibly mortality.86
Much of the combustible fuel exposure is related to poor
housing conditions such as overcrowding and poor ventilation when using BF. In addition to consistently conferring
a higher risk of the emergence of COPD, it also increases
the risk of acute respiratory infections.87 Women appear to
be particularly at risk to develop biomass-related COPD,
although environmental tobacco smoke may play a role.80
Meta-analyses have reported approximately twofold greater
odds of developing COPD in people exposed to BF.84,88
In a cohort study in the US, use of wood for indoor heating in fireplaces or woodstoves increases the risk of COPD
among current smokers, Caucasians, and men.89 These effects
remained even when controlling for age, smoking, and
educational level. Wood smoke may lead to greater risk of
developing COPD,90 whereas indoor use of coal for heating
may be more likely to increase the risk of lung cancer.91
Outdoor air pollution is also an important factor that
causes lung diseases in people of low SES as they tend to
live in poor housing, less desirable areas in close proximity
to highways, and pollution-producing manufacturers and are
2482
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therefore exposed to disproportionate amounts of inhalant
toxins. In the US, the estimated proportion of the population
living near a major highway was 4.2% for the poor, 3.7%
for the near-poor, and 3.5% for the nonpoor categories.92
In a longitudinal study of 4,757 women in Germany, it
was found that chronic exposure to PM10 and nitric dioxide
and living near a major highway led to an increased risk of
COPD (1.8-fold).20

Intrauterine and childhood exposures
Exposures, beginning with the fetus continuing throughout
childhood, can have an impact on the trajectory of lung
function development and ultimately long-term respiratory
health. Intrauterine exposure to tobacco as well as secondhand smoke in young people are important risk factors for
developing both asthma and COPD, especially in disadvantaged people.93–99 In the US, smoking rates in women
during the 3 months prior to pregnancy are similar to the
general population (~20%), decline to ~10% of women
while pregnant, and then increase close to pre-pregnancy
rates postpartum.100 Women of low SES tend to smoke more
during and after pregnancy. In a UK study, women of low
SES were three times more likely to smoke during pregnancy
than higher SES women.101 One study found a positive association between fetal size at 10 weeks gestation and FEV1
in 10-year olds.95 Another study found that smoking during
pregnancy, particularly in first trimester, is associated with
worse respiratory complications in children.102
Lung function impairment and respiratory symptoms after
birth and through childhood are also associated with asthma
occurrence in later years,95–97 ultimately increasing the risk
of developing COPD later in life.100,103 In children, chronic
exposure to air pollution is associated with a reduction in agerelated forced vital capacity and lung growth.104 However,
other studies found that there was no effect or inconclusive
evidence for longitudinal changes in lung function.94,105,106
A Swedish study of 2,278 children looked at the effect of
air quality during the first year of life on lung function at
16 years of age.93 Early life exposures to traffic-related air
pollution during the first year of life resulted in lower FEV1,
especially in males. Biomass smoke is also an independent
risk factor for COPD in people exposed in early life.84 Lastly,
impaired lung function in early adulthood is also associated
with an increased risk of developing COPD.107
It is also known that recurrent childhood respiratory
tract infections can lead to the development of lung diseases later in life108–111 and that low SES increases the risk
of childhood respiratory tract infections. In one study early
childhood respiratory infections as well as a history of
International Journal of COPD 2016:11
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asthma in the family were significant determinants of COPD
risk.110 A recent 50-year longitudinal study of a cohort of
children beginning at 10–15 years of age found that asthma
and wheezy bronchitis associated with viral infections led
to increased risk of developing COPD, while considering
smoking history.111

Health care access
Disparities in health care access persist despite efforts for
many years to improve care for underserved patients, ethnic
and racial minorities, and the underinsured. Access to health
care providers, diagnostic testing, and medications are often
more limited in disadvantaged people, although universal
health insurance in some countries lessen health disparities.
In addition to access being an issue in the low SES people,
lower literacy levels also impact their health status and
other outcomes.53
Shortage of primary care and specialist physicians in some
communities is an important factor for the unequal provision
of health care quality and access to health care services.112,113
In the US, Spain, and many developing countries, relatively
few pulmonologists and specialty services such as spirometry
and pulmonary rehabilitation are available to disadvantaged
people.8 In the US, minority patients with asthma are less
likely to be referred to specialists than whites.114
Access to health care is not the only important factor in
health disparities; the Black Report emphasized that despite
free health care provision through the National Health
Service, health disparities in mortality rates by social class
were evident.115 A US study showed that in people provided
with similar health insurance, those with low SES had worse
health outcomes than those at with high SES.31 In contrast, a
Canadian study found that there was no difference in COPD
mortality between people of low and high education – this
was felt to be due to universal health coverage and the greater
acute health care utilization by low SES people.116 Therefore,
it is not just a matter of providing health care resources at
a low cost to people of low SES, but it must involve other
additional strategies to promote healthy behaviors in these
patients and other contributors that affect health outcomes.
Disparities also exist in tobacco cessation advice
from health care providers.117,118 In a US study, compared
to Caucasian smokers, African–American and Hispanic
smokers were approximately two-thirds less likely to be
asked by their doctor about tobacco use and not have used a
cessation medication. These differences were unexplained
even when factors known to impact these rates were considered.117 In another study, low SES people were less likely
to receive provider-assisted assistance in stopping smoking
International Journal of COPD 2016:11
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than higher SES people.118 New quality outcome measures
requiring screening for tobacco use by health care providers
in the US have decreased this disparity.
Affordability and access to effective COPD medications is
a major barrier in many disadvantaged people. In some impoverished countries, the national formularies have very limited
choices for the treatment of COPD. One US study showed
that low SES people were only one-third as likely to have
used their inhaled tiotropium.46 An important problem with
COPD medication costs is the lack of availability of cheap
generics; in part because regulatory agencies, such as the US
Food and Drug Administration, have higher expectations for
inhaled generic equivalents than for oral generics.119

Clinical characteristics of COPD in
people of low SES
Both biomass and tobacco smoke are generated from the combustion of plant materials, which produce complex carbonbased particles and organic compounds such as hydrocarbons
and irritant gases. Biomass smoke increases the expression of
some matrix metalloproteinases similar to tobacco smoke.120,121
Like tobacco smoke, BF leads to chronic inflammation,
increased oxidative stress, and respiratory symptoms.122
Combined exposures to tobacco smoke and BF have additive
effects on the risk of developing lung diseases.90
Clinical features tend to differ between tobacco smokers
and people exposed to BF.61,123–126 In a study of women with
severe COPD, comparing wood smoke-related and tobacco
smoke-related COPD, there were no significant differences
between the two groups in terms of AO, resistance, or hyperinflation. However, bronchial hyper-reactivity was more evident
in the former.123 In another study, those exposed to BF scored
lower on the symptom and activity scores using a quality of
life assessment.61 This study also showed that women in the
biomass group had significantly more air trapping than the
tobacco group (radiologist score was 2.6 and 1.5, respectively)
and had lower oxygen saturation at rest and during exercise.
In another study in Columbia, South American women with
chronic bronchitis secondary to long-term wood smoke
inhalation, dyspnea, AO, air trapping, and increased airway
resistance were common.125 Additional research is needed
in this area as tobacco smoking becomes less prevalent and
other causes of COPD become more common.
Several studies have examined the radiologic and pathologic characteristics of biomass vs tobacco smoke-related
COPD.34,61,125–127 One study, using 3,706 multiethnic subjects
enrolled from six distinct US locations (Multi-Ethnic Study
of Atherosclerosis), examined the relationship among SES,
emphysema scores, and other measures.34 One-half of the
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subjects were current or former smokers, one-third had
occupational dust exposure histories, and one-third were born
outside the US. Those who did not complete high school had
more AO than those with a graduate degree, whereas, unexpectedly, the less well-educated people had a lesser extent
of emphysema. However, to what extent biomass exposures
contributed to this discrepancy was unclear. In a study of
43 Mexican women, grouped by tobacco smoking or BF
exposure, computed tomography (CT) scans showed that the
tobacco group had significantly more emphysema than the
biomass group (radiologist score was 2.3 vs 0.7; emphysema
on CT 27% vs 19%, and a larger size of emphysematous
spaces).61 In another study of Mexican women with COPD
secondary to wood smoke inhalation (n=12) vs smokingrelated COPD (n=10), pathological evidences of anthracosis,
chronic bronchitis, centrilobular emphysema, and pulmonary
hypertension were present in most patients exposed to wood
smoke.125 In an autopsy study of 48 Mexican COPD patients,
emphysema was less likely to be severe in BF patients than
in smokers.127 Small airways fibrosis was more evident with
BF, whereas increased goblet cell hyperplasia and emphysema were seen in smokers. Emphysema was more evident
in the smokers. In terms of survival, a 7-year follow-up study
showed that women with biomass-induced COPD have similar survival rates as men with tobacco-related COPD.124

Effect of SES on COPD outcomes
Table 4 lists the studies that show a strong association
between low SES and worse outcomes in COPD patients
including death, emergency department (ED) visits, hospitalizations, medication use, and health-related quality of
life.11,43,44,54–56,60,128 There may be sex differences as one study
reported that occupation and education were predictors of
death in men, whereas only education was significant in
women.43 In a systematic review, among several common
causes of death (COPD, diabetes, heart disease, all cancers, and stroke), the relationship with SES was strongest
for COPD-related deaths.55 However, with regard to lung
cancer (vs all cancers), the association between SES and
risk was also quite strong,128 therefore how various causes
of death are categorized may affect the reported association
between mortality and SES. A BOLD study analysis found
that smoking is the most important cause of AO, but airflow restriction was more associated with mortality in poor
countries.60 With regard to COPD mortality, people in lower
SES groups comprise between one-half to three-fourths of all
deaths where COPD is reported to be the primary cause.10,11,129
A recent Canadian study showed that the mortality gradient
between low and high SES is slowly widening (Figure 1).55 In
countries where current smoking rates continue to decline in
higher SES groups such as the US and Canada, although rates
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Figure 1 All-cause mortality rate by socioeconomic status among COPD patients in Canada from 1996/1997 to 2011/2012.
Note: Reprinted with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. Gershon AS, Hwee J, Victor JC, Wilton AS, To T. 2014.
Trends in socioeconomic status-related differences in mortality among people with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 11:1195–1202. The Annals of
the American Thoracic Society is an official journal of the American Thoracic Society.55
Abbreviation: COPD, chronic obstructive pulmonary disease.
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decline more slowly in disadvantaged people, this gradient
will likely widen even further. However, the impact of SES on
mortality is not seen with all COPD patient types. A UK study
found that mortality in alpha-1 antitrypsin patients was no
different as a function of educational status or occupation,130
likely because it is a genetically driven cause of COPD.
Other outcome measures that are affected by SES in COPD
patients are health-related quality of life,52 depression,48
medication (tiotropium and albuterol) use, ED visits,
hospitalizations, and burn injuries from home supplemental
oxygen.58 These disparities existed even in people who have
ready access to health care.10,31 Hospital readmission for acute
exacerbation of COPD (AECOPD), now a quality measure
in the US hospitals, is also more common in disadvantaged
COPD patients.49 A UK study, examining the relationship
between air pollution and albuterol prescriptions by primary
care physicians, found that deprivation was associated with
greater prescribing.131 Conversely, maintenance therapy use
is decreased in low SES people.46

Strategies to aid the diagnosis and
management of COPD patients
with low SES
There is an old adage in the US supposedly quoted from a
famous bank robber named Willie Sutton that evolved into
Sutton’s law used in clinical medicine. Sutton reputedly
replied to a reporter’s inquiry why he robbed banks that
“because that’s where the money is”.132 Translated into where
the greatest opportunities and challenges exist for COPD, it
is targeting low SES populations and that is where the money
and other resources need to be directed.
In reality, to make substantive changes in COPD risk factors and social determinants of health, health equity strategies
must be part of larger, multifaceted efforts that will always
depend on societal changes that can be very difficult to
achieve. Broadly speaking, there are three important principles
that should be included in the strategies to improve COPD
health equity: 1) include all stakeholders in the development
and implementation of interventions; 2) adapt interventions
to address the unique barriers and facilitators of the disparate
population; and 3) create implementation strategies targeting all levels of the socioecologic framework – individual,
interpersonal, organizational, community, and public policy.
Stakeholders can vary from government agencies, health
care organizations such as WHO, ATS, ERS, health insurers,
health care institutions, research organizations, health care
providers, patients, and community groups. The remainder
of this section focusses approaches that may be applied by
individuals or in local settings.
International Journal of COPD 2016:11
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Some strategies that might be employed include 1) prioritize population screening and case-finding in people of low
SES to identify symptomatic people with exposure histories in
this high-risk population; 2) undertake educational efforts in
people with low SES using culturally sensitive strategies
in local communities; optimally beginning at a young age
regarding the use of tobacco products, indoor biomass,
second-hand smoke, and COPD; 3) provide alternatives to
the use of indoor biomass cooking; 4) identify cost-effective
strategies for health care in this population; and 5) identify
existing and potential strategies to save medication costs and
optimize adherence.

Organizational strategies
The WHO, ATS, ERS, Forum of International Respiratory Societies, and European COPD Coalition are among
the health care organizations that are responding to the
problems surrounding COPD and SES. Some key ATS
efforts targeting health disparities include establishing a
group called the Lung Corp,133 publishing a perspective of
respiratory health equality in the US,134 and a joint policy
statement with ERS on disparities in respiratory health.8 The
ATS created the Lung Corps to reduce health disparities
through the promotion of research, training, disseminating
best practices and monitoring, and advocating lung health
to the public. In addition, an ATS subcommittee reported
that attainment of respiratory health equality necessitates the
end of disparities, which would require a multidisciplinary
effort targeting environmental exposures, encouraging
healthy lifestyles, and optimizing the prevention, screening, diagnosis, and management of lung diseases.136 A joint
ATS/ERS policy statement8 describes actions including
developing educational programs for health care providers
and policy makers to reduce disparities, holding conferences addressing health care disparities, and collaborating
with other organizations such as the WHO. ATS/ERS
jointly plans to decrease disparities by 1) guiding research
agendas, 2) increasing healthcare provider awareness of
disparities, 3) advocating for appropriate policies, and 4)
tracking progress with disparities. Nearly 2 decades ago,
ATS developed the Methods in Clinical and Operational
Research program to increase the numbers of public health,
academic, and clinical leaders to facilitate research and its
application in public health and health care to respiratory
diseases in various countries. The recent ATS/ERS research
priorities publication did not address health disparities as
one of the research priorities, but did state that the natural
history of the disease should be studied with regard to race,
sex, and SES.135
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The Forum of International Respiratory Societies
developed a guide on preventing and treating lung diseases,
including COPD.136 Principal recommendations include
increase public awareness, target environment and tobacco,
increase public health and clinical research, and train more
health care providers globally to deal with lung diseases.
It also recommended developing cost-effective management
protocols for COPD in low-income settings. The European
COPD Coalition has published a call for action among
countries in the European Union to better target COPD.137
Among multiple recommendations, it was stated that the
European Union should support and initiate research on
social and environmental determinants of health to better understand factors that increase the risk of developing
COPD in Europe.
The WHO has a number of publications addressing COPD
and SES including an essential medicine list, tobacco prevention strategies, guidelines to reduce indoor BF exposure,
prevention of chronic respiratory tract diseases, and managing
COPD in low SES settings.138–143 WHO recommendations for
the diagnosis and management of COPD in low SES settings
by primary care providers have been published.142 Considering the lack of availability of spirometry in many low-income
settings, WHO recommends the use of clinical history and
peak expiratory flow measurement to guide the diagnosis
of COPD. Severity of COPD is judged based on symptoms.
Education of the patient and family is recommended regarding biomass fuels, occupational exposures, and tobacco
smoke. Recommended drug therapies included short-acting
β2-agonists and low dose oral theophylline. They also state
that ipratropium may be an option, but may be too expensive.142 Regarding tobacco, WHO embraces the MPOWER
acronym approach for tobacco: Monitor tobacco use and
prevention policies, Protect people from tobacco smoke,
Offer help to quit tobacco use, Warn about the dangers of
tobacco, Enforce bans on tobacco advertising, promotion,
and sponsorship, and lastly Raise taxes on tobacco.139 Goals
of the WHO Strategy for Prevention and Control of Chronic
Respiratory Diseases are to improve 1) surveillance to map
and analyze the determinants with particular reference to
poor and disadvantaged populations and to monitor the future
trends, 2) primary prevention to reduce the level of exposure
of individuals and populations, and 3) secondary and tertiary
prevention to strengthen health care for people with chronic
respiratory diseases.141 WHO also provides a list of essential
medicines for many diseases that is updated every 2 years.138
Additionally, the WHO has begun a noncommunicable
chronic diseases monitoring system for .190 countries.143
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Surveillance
Opportunities for surveillance include expanding epidemiologic studies in more low SES settings and using these
data to aid efforts such as to screen for undiagnosed disease.
Despite the tremendous global burden of chronic respiratory
disease, there are relatively limited data on its prevalence,
natural history, and associated morbidity and mortality of
COPD in LMICs.144 However, there has been significant
progress in defining the prevalence and impact of COPD
globally through surveillance studies – particularly with
the newer BOLD and PLATINO international studies,
additional studies in Africa,145 and in the US with the expansion of the Behavioral Risk Factor Surveillance System for
COPD prevalence.146,147
Ideally, each surveillance system should be capable of
describing disease prevalence and disease impact in disparate
people as well as the overall population. Furthermore, the
information must be communicated to appropriate people
including policy makers, health care providers, and the population from which the data were derived. This is largely a
role of the public health sector in collaboration with others
involved in health care provision. In general, the lay public’s
knowledge of COPD is far less than that of other diseases
such as asthma, cancer, and heart diseases;148,149 therefore,
it is imperative to educate the general public about COPD,
partially relying on these surveillance data. Ideally, this
education should occur throughout the population including
the educational systems of young people.
One proposed strategy is to provide annual reports on
lung health surveillance data from vulnerable, disparate
populations.150 The WHO has recently begun a multinational
surveillance of chronic diseases to better monitor low SES
populations.143 In the US, a Nationwide Framework for
Surveillance of Cardiovascular and Chronic Lung Diseases
recommends to provide such data through surveillance
to analyze disparities in disease prevalence, risk factors,
outcomes, and health care delivery. It was recommended to
integrate various surveillance systems into a central system
that is able to function nationally and locally.151 In addition
to the use of the Behavioral Risk Factor Surveillance System health survey, the US Centers for Disease Control and
Prevention also recently expanded surveillance for COPD
through the use of chronic disease indicators.152 The chronic
disease indicators are used by epidemiologists at local, state,
and national levels in the US to monitor many major chronic
diseases. The updated indicators are 1) mortality of COPD as
a primary or secondary cause, 2) COPD prevalence, 3) ED
visits with COPD as a primary or secondary cause, and 4)
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hospitalizations as a primary or secondary cause. Previously,
only mortality was included in these measures; inclusion of
COPD as comorbidity in surveillance of other diseases will
provide greater perspective of its impact across health care.

Primary prevention
Of all possible interventions, primary prevention for COPD
through the avoidance of exposure to inhalant toxins would
have the most impact on this disease; however, this is difficult to achieve in disadvantaged people. Both strategies and
interventions are necessary to target low SES communities
by improving housing conditions, providing education on
tobacco in people at a young age, reducing tobacco use, and
reducing other detrimental environment exposures, however,
interventions are not often implemented.
To have an impact on tobacco use in the low SES population, it will require societal changes and efforts by health
care organizations, public health, and individual providers.
Societal interventions that can impact tobacco use include
raising taxes on cigarettes, banning the use of tobacco
in certain settings such as health care facilities, schools,
government facilities, restaurants, and bars, and restricting advertisement.100 A study conducted in one US state
showed that communities with smoke-free public policies
had significantly lower rates of COPD hospitalizations.153
A recent Cochrane Review reported that national smoking
bans in 21 countries led to improvement in multiple outcome
measures.154 Because people who are more educated smoke
tobacco at much lower rates, it is logical that improving
secondary and tertiary education programs for the low SES
population would contribute significantly to lower smoking
rates. Education access and performance are heavily determined by family background, including family income and
environment, which can strongly influence cognitive and
noncognitive abilities.
As a whole, health care providers perform suboptimally
in assisting patients to quit smoking. A 2007 report by the
American Association of Medical Colleges on physician
behavior showed that most physicians consistently ask
patients about their smoking status and advise them to stop
(86%) if a smoker, but steps afterward were infrequent.155
Physicians indicated the tools, training, and resources to aid
patients effectively in stopping smoking are inadequate.
There are limited studies evaluating smoking cessation interventions in low-income people.156,157 One study
used a systematic, telephone-based intervention involving
counseling, nicotine replacement therapy, and community resources, to double the quit rates (17% vs 8%).156
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Identifying and reaching out to poor people in their local
communities was an important part of this program. In
reality, typical interventions should be effective, but there
is such a large number of smokers who are of low SES, and
they are less inclined to quit, therefore the task is large. A
national smoking cessation approach in Denmark was able
to achieve reasonable abstinence rates in low SES people,
however were still 30% lower in the low education vs the
high education group.157
Perhaps idealistic, the best approach for a physician
to effectively facilitate smoking cessation is as follows:
1) ensure determination of smoking status, 2) the provider
and other team members advise smoker to quit, 3) if the
patient is willing, the prescriber initiates further steps with
a simple prescriptive order, where drug therapy and counseling resources are available and are provided directly to
the patient thereafter, and 4) the provider sees the patient
in follow-up. Unfortunately, there are multiple barriers
inhibiting this optimistic model in many settings, much of
it are resource based. Of note, the WHO essential medicine
list includes nicotine replacement therapy. In the US, the
cost of nicotine replacement therapy is comparable to the
costs of smoking 20 cigarettes per day; therefore, cost of
this therapy should be no different than that of smoking for
most people.
Household air pollution is a modifiable exposure for
which specific interventions such as the use of improved fuels
(higher on the fuel ladder) for cook stoves, gas lighting, or
heaters may be effective in lowering the risk of COPD.158
The WHO provides guidelines for lowering indoor exposure
to burning BF.140 Some of the key recommendations include
1) exposure to fine particulate matter (PM 2.5) should not
exceed 0.23 mg/min when unvented (eg, without a chimney
or hood) and 0.80 mg/min when vented (eg, with a chimney
or hood); 2) amount of carbon monoxide should not exceed
0.16 g/min for unvented devices and 0.59 g/min for vented
devices; 3) unprocessed coal should not be used as an indoor
fuel; and 4) kerosene should not be used as an indoor fuel.
The WHO recommends biogas, ethanol, liquefied petroleum
gas, and natural gas as safer alternative fuels. In addition to
cleaner fuels, vented, more efficient biomass stoves might
also serve to decrease indoor exposure. There is an international effort to bring safer BF in homes by the UN Foundation
Global Alliance for Clean Cookstoves and the Climate and
Clean Air Coalition.159 Unfortunately, the less expensive
fuel options are generally less efficient fuels, produce more
smoke, and are used by people with the most poorly designed
homes. Cleaner fuels such as propane or liquid petroleum
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gas burn very cleanly, but are often too expensive for many
impoverished households.
A number of studies show that reducing BF exposures
improves respiratory outcomes. In 2011, a randomized,
controlled study (RESPIRE 6) showed that a reduction in
disease activity is possible – in this case, there was a decrease
in severe pneumonia in children after a chimney stove
intervention to reduce indoor air pollution.160 Romieu et al
conducted a trial in .500 Mexico women to evaluate the
effect of a chimney wood stove intervention vs the traditional
open fire stove on respiratory symptoms and lung function.161
Although the adherence was poor (50%), use of the chimney
stoves reduced respiratory symptoms (rate ratio of 0.29 for
wheezing) and decline in lung function (31 vs 62 mL) over
a 1-year period compared with those using open fire.161 In
another study, investigators from the People’s Republic of
China followed participants for up to 9 years and found that
using biogas instead of biomass for cooking reduced the
annual decline of FEV1 by 12 mL per year and improved
kitchen ventilation reduced the decline by 13 mL per year,
compared with those who took up neither intervention.162 One
study in Columbia, South America, showed that conversion
to natural gas heating led to a reduction in outpatient visits
and hospitalizations for COPD.163 In the US, the Environmental Protection Agency has new recommendations on indoor
wood stoves to decrease particulate emissions.164
Although ambient air pollution has well-documented
the adverse effects on patients with COPD, the evidence for
air pollution as a cause of COPD is inconclusive.87 A study
before and during the 2008 Beijing Olympics showed that
the risk of asthma outpatient visits declined with lower ozone
levels that occurred with changes in automobile use and
manufacturing preceding and during the games.165 Regarding air pollution, minimizing exposure on poor air quality
periods may aid in lessening the symptoms or preventing the
exacerbations in COPD patients. Therefore, having daily,
easily accessible air quality reports to the general population
including people with lung disease is valuable, particularly
for those with severe disease.
Prevention through appropriate immunizations can
improve outcomes in the COPD population from influenza
and pneumococcus infections.166 Pertussis can be associated
with AECOPD,167 but there is no evidence that vaccination
can decrease the risk of AECOPD. Like many other aspects
of health care in low SES, immunizations are less likely to
be administered appropriately in disadvantaged people in
most,168,169 but not in all settings.170 Countries with fully funded
immunization programs have higher rates of utilization.170
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Health care access
Access to health care is a common barrier to good health
in disadvantaged people because of the lack of resources
and local availability of primary care and specialists. This
is particularly true in rural areas, where a significant segment of the COPD population resides. Too often, care for
disadvantaged people occurs in EDs, where care is very
costly and not optimal as the principal site of health care for
COPD patients. In the UK, a survey showed that the majority
of patient contact with health services occurs via either the
general practitioner or an emergency admission to hospital.171 The development of a National Service Framework
for COPD in the UK has set goals to improve the quality
and access to COPD services as well as to reduce inequalities and health care utilization costs.172 A study by Lisspers
et al in Sweden showed that incorporating specialist nurses
in asthma/COPD clinics decreased AECOPD in patients
without additional secondary specialist care.173 Researchers from Plymouth University in the UK are undertaking a
project in several LMICs to improve access to health care
to prevent and manage chronic lung diseases including
nontraditional pulmonary rehabilitation clinics, smoking
cessation programs, and involving local midwives.174 The
project, FRESH AIR, will adapt and test innovative ways
to implement evidence-based practice in the prevention,
diagnosis, and treatment of chronic lung disease in several
LMICs. A study in Pakistan plans to target low resource
settings using various approaches such as providing COPD
care in the existing tuberculosis clinics.175
Studies looking at the impact of telemedicine have been
equivocal in improving access to health care and outcomes
in COPD.176 Telemedicine is more challenging in low SES
people for various reasons. For example, the poor and
elderly tend to use cheaper, less “smart” phones, and therefore, technology may not be compatible with the COPD
patients’ technological capabilities.
Educating more respiratory specialists, including
minority providers, is needed as rural and poor areas
lack pulmonary specialists in many countries. Little has
been published regarding the geographic distribution of
specialists and therefore availability of care for low SES
COPD patients.8 The ATS, ERS, and Forum of International Respiratory Societies support better education and
availability of providers available to COPD patients. They
want to ensure that medical and other health care students
are taught about the association between COPD and SES.
Postgraduate education regarding disparities is also needed
at multi- and interdisciplinary conferences for health care
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providers, public health practitioners, health agencies, and
others in every country to address SES and lung diseases
in an ongoing basis.

Screening and diagnosis
Since the majority of people with undiagnosed COPD have
low SES, undertaking population screening or case-finding in
targeted communities or health care settings is desirable. There
are a number of screening and case-finding questionnaires
that can identify people at high risk of COPD.177–181 Although
smoking history is always addressed, most do not include
questions about BF or occupational exposures.183 A COPD
screening questionnaire was developed in the People’s
Republic of China, which included both smoking and exposure to BF from cooking but did not include occupational
exposures.181 The BOLD and PLANTINO studies’ questionnaires included occupational exposures and smoking history,
but not BF.62,182 To make COPD case-finding or population
screening most applicable globally, it is imperative to develop
and validate such questionnaires that include all three major
categories of COPD risk factors – tobacco, occupation, and
BF exposures. In general, the sensitivity of such screening/
case-finding questionnaires can be improved with portable
flow meters that measure FEV1 and FEV6.183
Diagnostic resources for COPD in LMICs are poor;
therefore, diagnoses are often made on the basis of clinical
features alone, which is a distinct limitation for a disease that
by the strictest definition requires documentation of AO. One
Chinese study did use discriminant function analysis, not
relying on spirometry, by using nine patient characteristics
including smoking history, occupation, and rural vs urban
residence, to screen for COPD in impoverished areas. The
sensitivity was reported to be ~90% based upon AO measured
by spirometry. One study showed the benefits of screening
for undiagnosed COPD in different socioeconomic practice
settings.184
The WHO published specific guidelines to aid primary
care providers in low-income populations for the diagnosis
and management (Figure 2) of COPD.142 In situations where
diagnostic spirometry is limited, WHO recommends to make
a diagnosis based on age, clinical history (persistent respiratory symptoms and chronic productive cough), and exposure
history (.1 ppd ×15 years). Although debatable, it was also
recommended that peak flow meters can be used to determine
AO reversibility and thus help differentiate between asthma
and COPD. However, portable spirometers that can measure
peak flows, FEV1, FEV6, and/or forced vital capacity are now
fairly inexpensive.
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Treatment
The care offered to low SES patients with chronic respiratory
disease is not always based on research or best practices.
Often, access to optimal COPD treatments, such as availability to primary and specialist providers, smoking cessation counseling, supplemental oxygen, and noninvasive
ventilation, is limited in these people. The WHO published
guidelines for the treatment of asthma and COPD by primary
care providers in resource-limited settings.142 It was designed
to aid easy access and facilitate implementation in busy community clinics and small hospitals. It provides recommendations for acute and chronic management of COPD. Patient
education regarding preventive measures such as stopping
smoking tobacco products, use of well-ventilated areas for
cooking and heating, as well as awareness about high-risk
occupations is recommended. The recommended drug
therapies are few and by most developed country’s standards
would probably be considered to be suboptimal.
One important goal to optimally treat COPD patients is
to properly diagnose and manage comorbidities common to
this population. Early identification and optimal treatment of
heart disease, lung cancer, depression, and obstructive sleep
apnea can improve outcomes. Heart disease and lung cancers
are more common in COPD, which more likely occur in low
SES people. Cardio-selective B-blockers, when prescribed
for some types of heart disease, reduce the overall mortality in
COPD.185 Unfortunately, too often practitioners are reluctant
to prescribe these agents for COPD, although the cardioselective agents have a low risk of worsening AO.186 These
agents are available generically and are relatively affordable.
In the US, low-dose chest CT screening has commenced in
high-risk people to identify early lung cancer and decrease
the associated mortality; however, this is quite expensive.187
Obstructive sleep apnea occurs in COPD at about the same
rate as the comparable patients in general population but
is more common in low SES patients.188 Patients with coexisting COPD and sleep apnea typically develop more
severe oxygen desaturation during sleep and have worse
outcomes.189 Treatment of severe obstructive sleep apnea is
most effectively done with noninvasive ventilation, although
costs may be prohibitive.
Efforts to educate the general public and COPD patients
are sorely lacking, particularly for impoverished people.
Only recently, education about COPD to the general public
has been undertaken in the US, whereas much more has been
done to educate the public about asthma. Education about
smoking, BFs, and the disease COPD should start as early
as primary schools; however, health literacy is a major issue
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Management of exacerbation of COPD
Antibiotics: should be given for AECOPD (strong recommendation, very low-quality evidence)
Oral steroids: a short course of prednisolone is recommended for severe AECOPD (eg, prednisolone 30–40 mg for about 7 days
(strong recommendation, very low-quality evidence)
Inhaled beta agonists: higher doses of inhaled salbutamol should be administered via a nebulizer or spacer (strong recommendation,
very low-quality evidence)
Oxygen: if available, oxygen should be administered by a device that controls concentration of 24%–28% (strong recommendation,
very low-quality evidence)
Intravenous aminophylline: based on the available evidence, IV aminophylline not recommended in AECOPD. Little evidence of
benefit; any beneficial effect is likely small and outweighed by ADRs (strong recommendation, very low-quality evidence)
Stable management
Short-acting beta-agonists: are effective in improving symptoms in patients with stable COPD. Prescribe as required. No data to
assess the optimum frequency of administration or the effect of regular administration. Oral B-agonists not recommended (weak
recommendation, very low-quality evidence)
Theophylline: unlikely that blood levels can be monitored in resource-constrained settings, only low doses of theophylline are
recommended. Patients should be advised about ADRs (weak recommendation, very low-quality evidence)
Oral corticosteroids (prednisolone): are ineffective in stable COPD except possibly in high doses when there are important side
effects. On the basis of benefits and risks, oral steroids are not recommended for use in stable COPD (strong recommendation, very
low-quality evidence)
Inhaled steroids (beclomethasone): when given in high doses, there may be a small benefit from ICS; however, high doses are
expensive for resource-poor countries and high doses have more ADRs, including pneumonia. Risks are unknown in areas where the
prevalence of HIV and tuberculosis are high. Since the benefit is modest, the risk/benefit ratio is much higher than it is for asthma. The
use of ICS for patients with stable COPD therefore cannot be justified. Not recommended (strong recommendation, very low-quality
evidence)
Ipratropium bromide: when compared to regular short-acting beta agonists, short-term inhaled ipratropium bromide has small benefits
in reducing symptoms and improving lung function. Currently, ipratropium preparations are more expensive than beta agonists,
and there are no data to assess risk versus benefits of regular use over longer periods to recommend long-term regular use. Not
recommended (weak recommendation, very low-quality evidence)
Figure 2 World Health Organization drug therapy guidelines for managing acute exacerbations of COPD and stable management in resource limited settings.
Note: Reprinted from World Health Organization. Prevention and control of non-communicable diseases: guidelines for primary health care in low-resource settings.
Copyright 2012.142
Abbreviations: ADRs, adverse drug reactions; AECOPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency
virus; ICS, inhaled corticosteroid; IV, intravenous.

in some of these children and their families. Education about
COPD and its risk factors should be culturally sensitive and
at the appropriate education level for the target population.
A study in a primary care setting showed that COPD patients
with a high-school or less education, capable of communicating or writing, were able to be successfully educated about
their disease.190
Poor access to medications and noncompliance are major
factors that limit the optimal management of obstructive
lung diseases.191,192 Identifying cost-effective drug therapy
strategies will vary among different settings and countries;
health care providers should explore what the options are in
their local settings. Essentially, all evidence-based COPD
medications are more limited in resource sparse settings and
even the most basic medications have variable availability.
This is true despite the overall cost-effectiveness of interventions such as smoking cessation counseling combined
with drug therapy or maintenance drugs that can decrease
AECOPD. It is well documented that maintenance medications for COPD can improve respiratory symptoms and
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quality of life and decrease AECOPD1 and that medication
adherence can improve mortality.193 There is little definitive data supporting that these medications can modify the
course of COPD; however, it could be a function of identifying phenotypes and genotypes with which drug therapies
could slow down the progression of the disease and improve
survival. Currently, interventions with the most mortality
benefits relevant to COPD include 1) long-term supplemental
oxygen, 2) smoking cessation, 3) lung transplantation, and 4)
optimizing prevention or management of key comorbidities
such as heart disease – the latter three include medications.
Annually, the WHO publishes an updated essential medicine list that includes the most basic drug therapies relevant
to the acute and chronic management of COPD.194 Even for
these therapies, disadvantaged persons have substantial challenges in accessing and paying for COPD medications as well
as being adherent with their therapies. The most basic drug
therapy, albuterol, can account for a high portion of personal
income in LMICS, often as much as several days wages.144
In the US, drug costs can also be quite substantial for a person
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Table 5 Drug costs relative to days of work in low-income people in the US
Measure

Albuterol MDI
(200 inhalations)

ICS/LABA inhalera

LAMA inhalera

Albuterol + ICS/
LABA + LAMA

Retail drug costsb
Days of work required to pay for
medication(s) using ~ minimum wagec

$55.00
0.86 days

$340.00
5.3 days

$320.00
5 days

$715.00
11.2 days

Notes: aOne month supply. bApproximate retail costs with no subsidies were obtained from www.goodrx.com. Accessed February 1, 2016.197 cAnnual income of $16,640
(based on a minimum wage salary of $8/hour at 40 hours/week).
Abbreviations: MDI, metered dose inhaler; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting antimuscarinic agent.

living in poverty. In an advanced COPD patient, a triple
drug regimen could cost nearly half of a monthly personal
income without health insurance subsidies (Table 5). Even
when subsidized by insurers, the poor often choose between
basic living necessities vs appropriately using their prescribed
COPD medications. One strategy in the US to decrease drug
costs for retired or disabled COPD patients, covered by the
federal Medicare insurance program, is to prescribe nebulized
albuterol, ipratropium, formoterol, arformoterol, and/or
budesonide if they fail the same drugs through an inhaler.
Different settings may have resources available to uniquely
help lower the drug costs.
An important contributor to unaffordability of COPD
medications is the lack of generic versions for the majority of
drugs used to chronically manage COPD. In contrast, many
of the prominent maintenance medications for cardiovascular
diseases and other major chronic diseases often have cheaper
generic drugs. In the US, this is affected by Food and Drug
Administration requirements for new “generic” inhalers.
Somewhat extensive and expensive studies are mandated
for generic inhalers by the US Food and Drug Administration, often taking years to bring to market. The European
Medicines Agency has less strict requirements to bring a
generic inhaler to the market. It has been suggested that
regulatory agencies among different countries share and
accept submitted pharmaceutical company dossiers among
themselves through harmonizing regulations. This has been
the major impediment toward declaring a “global worldwide
reference product” that generic pharmaceutical companies
could use in their development.119
It is well-documented that people with low SES have
significantly worse medication adherence, including for
COPD. There are multiple contributors including commercial
availability, costs, and health behaviors that affect adherence.
Medication adherence is a function of numerous factors, and
in general people of a low SES tend to be the most noncompliant.195 This is partially due to lack of resources in some
people, however, occurs even in an insured indigent. In a study
of a US health system in adults with health care insurance, it
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was found that medication adherence was poorest in people
with low education level; and further patients with asthma or
COPD had the worse adherence compared with chronic diseases such as depression and diabetes mellitus.31 In 2006, one
study found that tiotropium was used less frequently in people
with low vs high SES (odds ratio =0.3),46 whereas in another
study albuterol use was prescribed more often in highly polluted areas where the poor live.131 An excellent review on
access to essential medicines for obstructive lung diseases and
related issues in disparate settings was published in 2015 by
the Forum of International Respiratory Societies.196

Conclusion
Across the globe, COPD disproportionately affects ethnic
minorities and low socioeconomic groups. Vulnerable populations have differential exposure to indoor and outdoor pollution, occupational and environmental hazards, and tobacco
smoke, which contribute to disparities in prevalence of COPD
and outcomes. However, social determinants of health (ie,
access to health care, education, economic stability, social
and community context, and neighborhood/built environment)
add an additional barrier to establishing health equity. Consequently, interventions that are designed to improve health
equity should be adapted for the socioeconomic and political
context in which the vulnerable problems exist. Each setting,
whether it is the individual clinic setting, health care system,
community, region, and country, has its unique influences and
resources that will determine the best approaches to lessen the
burden of health disparities related to COPD. Whether it is at
the health care provider–patient level, the health care organization level, or societal level – it has been and will continue to be
a challenge to lessen the disparities associated with COPD and
SES, if no other reason, the availability of adequate resources.
No one sector will solve the issues with disparities regarding
COPD. Eventually, COPD will be a disease of predominantly
the low SES segment of the population, whether caused by
tobacco or biomass or occupation. The question is going to
be how significant a role the disease plays, which depends on
resources, programmatic approaches, and individual health
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care and public health providers and societies. However, when
it comes to health care costs, being poor is expensive. We
have largely “diagnosed the syndrome of health disparities
in COPD”, and evidence-based strategies that address SES
are greatly needed to decrease disease burden.
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